1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 15
Sponsor: Other
Protocol IDs: GMALL05, NCT00199082
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 and under
Sponsor: Other
Protocol IDs: LAL-BR/2001, NCT00526175
|
|
5.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: PETHEMA-LAM07, NCT01041040
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: sim201002, NCT01211002
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: Any age
Sponsor: Other
Protocol IDs: UKM08_0057, 2009-018072-33, NCT01424839
|
|
8.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 55 and under
Sponsor: Other
Protocol IDs: LAL Ph-2008, NCT01491763
|
|
9.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011, NCT01501136
|
|
10.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 14 to 70
Sponsor: Other
Protocol IDs: hnslblzlzx2011-2, NCT01501149
|
|
11.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: HDE-ALL-2011, NCT01457040
|
|
12.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Haema CBF SCLC UK/AS 01, NCT00168896
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: Other
Protocol IDs: MT2006-13, 0607M89052, UMN-MT2006-13, NCT00630565
|
|
15.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 0 to 30
Sponsor: Other
Protocol IDs: EUDRACT 2005-002618-40, BfArM-4030755, EC-105/05, DKS 2006.01, DK 2008.17, NCT00749723
|
|
16.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and under
Sponsor: NCI
Protocol IDs: COG-ANHL1131, ANHL1131, NCT01595048
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: NCI
Protocol IDs: SWOG-S9704, CAN-NCIC-LY11, CALGB-59903, ECOG-S9704, S9704, NCT00004031, LY11
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: CKTO-2000-06, HOVON-44, HOVON-44/CKVO-2000-06, EU-20042, ISRCTN95614846, NCT00012051
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Under 50
Sponsor: NCI, Other
Protocol IDs: CDR0000068608, EURO-EWING-INTERGROUP-EE99, EBMT-INTERGROUP-EE99, EORTC-62981, GPOH-AUSTRIA-INTERGROUP-EE99, GPOH-GERMANY-INTERGROUP-EE99, SFOP-INTERGROUP-EE99, SWS-SAKK-INTERGROUP-EE99, CCLG-INTERGROUP-EE99, COG-AEWS0331, EU-20213, AEWS0331, NCT00020566
|
|
20.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 20 at diagnosis
Sponsor: Other
Protocol IDs: CDR0000069191, SIOP-EUROPE-HR-NBL-1, ESIOP, EU-20148, NCT00030719
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and under
Sponsor: Other
Protocol IDs: CDR0000257531, SIOP-WT-2001, SFOP-SIOP-WT-2001, CCLG-SIOP-WT-2001, GPOH-GERMANY-SIOP-WT-2001, EU-20208, NCT00047138
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 16
Sponsor: Other
Protocol IDs: CDR0000416124, FRE-FNCLCC-GETUG-13/0206, EU-20502, NCT00104676
|
|
23.
|
Phase: Phase III
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: CALGB-50303, ECOG-50303, NCI-05-C-0252, NCT00118209
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: DSHNHL 2002-1, NCT00129090
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MCL2004-2, NCT00209222
|
Mobile | Español
